RCKTW · Insider Trading

Rocket Pharmaceuticals, Inc. Warrant

Every open-market purchase and sale reported by RCKTW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
2
code P
Sales
24
code S
Reporting Insiders
20
current holders
RCKTW — Recent Form 4 Transactions (latest 2026-05-28)
FiledInsiderRole TypeSharesValue
2026-05-28 John Militello See Remarks MIXED −121,694 deriv. —
2026-05-26 Gaurav Shah CEO MIXED +20,806 −$42.50K
2026-05-21 John Militello See Remarks Sell −384 −$1.16K
2026-05-21 Martin Wilson General Counsel Sell −662 −$2.00K
2026-05-21 Gaurav Shah CEO Sell −2,409 −$7.26K
2026-05-14 John Militello See Remarks Sell −855 −$3.08K
2026-05-14 Martin Wilson General Counsel Sell −3,361 −$12.12K
2026-05-14 Gaurav Shah CEO Sell −2,728 −$9.84K
2026-05-11 Sarbani Chaudhuri See Remarks Sell −17,650 −$67.74K
2026-02-20 John Militello See Remarks Sell −1,157 −$3.86K
2026-02-20 Gaurav Shah CEO Sell −5,990 −$19.99K
2026-02-20 Martin Wilson General Counsel Sell −1,376 −$4.59K
2026-02-18 John Militello See Remarks Sell −3,726 −$12.34K
2026-02-18 Martin Wilson General Counsel Sell −12,253 −$40.58K
2026-02-18 Gaurav Shah CEO Sell −12,279 −$40.67K
2026-02-13 John Militello See Remarks A +29,982 —
2026-02-13 Martin Wilson General Counsel A +311,813 —
2026-02-13 Gaurav Shah CEO A +286,028 —
2026-02-13 Christopher James Stevens Chief Operating Officer A +61,963 —
2026-02-13 Syed Ali-aamir Rizvi Chief Medical Officer A +61,963 —
2026-02-13 Sarbani Chaudhuri See Remarks A +125,924 —
2026-01-06 Elisabeth Bjork Director Buy +10,000 +$34.40K
2025-11-20 Martin Wilson General Counsel Sell −1,646 −$4.91K
2025-11-20 John Militello See Remarks Sell −1,086 −$3.24K
2025-11-20 Jonathan David Schwartz See Remarks Sell −2,545 −$7.59K
2025-11-20 Gaurav Shah CEO Sell −6,276 −$18.72K
2025-11-10 Martin Wilson General Counsel A +100,000 —
2025-10-16 John Militello See Remarks Sell −28,918 −$114.58K
2025-10-08 Syed Ali-aamir Rizvi Chief Medical Officer A +345,911 —
2025-10-03 Peter Fong Director A +53,333 —
2025-09-23 RTW INVESTMENTS, LP Director MIXED — +$38.45M
2025-09-09 Martin Wilson General Counsel A +150,000 —
2025-09-09 Jonathan David Schwartz See Remarks A +80,000 —
2025-09-09 John Militello See Remarks A +40,000 —
2025-08-27 Elisabeth Bjork Director Buy +10,000 +$34.10K
2025-08-20 John Militello See Remarks Sell −1,060 −$3.22K
2025-08-20 Martin Wilson General Counsel Sell −1,592 −$4.84K
2025-08-20 Gaurav Shah CEO F −2,234 −$6.81K
2025-08-20 Jonathan David Schwartz See Remarks Sell −2,485 −$7.56K
2025-08-18 Martin Wilson General Counsel Sell −12,109 −$36.56K
2025-08-18 John Militello See Remarks Sell −7,043 −$21.26K
2025-08-18 Jonathan David Schwartz See Remarks Sell −11,161 −$33.70K
2025-08-06 Christopher James Stevens Chief Operating Officer A +407,166 —
2025-07-18 Mikael Dolsten Director A +30,000 —
2025-07-18 Carsten Boess Director A +30,000 —
2025-07-18 Elisabeth Bjork Director A +30,000 —
2025-07-18 Piratip Pratumsuwan Director A +30,000 —
2025-07-18 David P Southwell Director A +30,000 —
2025-07-18 Roderick Wong Director A +47,667 —
2025-07-18 Fady Ibraham Malik Director A +30,000 —
RCKTW — Current Insider Holders
InsiderRole Shares HeldValue
RTW INVESTMENTS, LP Director 18,236,124 $36.47K
Roderick Wong Director 18,236,124 $36.47K
Gaurav Shah CEO 1,467,962 $2.94K
Gotham Makker Director 1,036,846 $2.07K
Martin Wilson General Counsel 677,977 $1.36K
Kinnari Patel See Remarks 573,628 $1.15K
Christopher James Stevens Chief Operating Officer 469,129 $938
Syed Ali-aamir Rizvi Chief Medical Officer 407,874 $816
Jonathan David Schwartz See Remarks 299,064 $598
Sarbani Chaudhuri See Remarks 267,510 $535
David P Southwell Director 144,784 $290
Aaron Ondrey Chief Financial Officer 128,173 $256
John Militello See Remarks 89,780 $180
Pedro P Granadillo Director 54,734 $109
Peter Fong Director 53,333 $107
Elisabeth Bjork Director 50,000 $100
Mikael Dolsten Director 44,220 $88
Fady Ibraham Malik Director 30,000 $60
Carsten Boess Director 30,000 $60
Piratip Pratumsuwan Director 30,000 $60
RCKTW Insider Trading FAQ
Who are the insiders at RCKTW?
20 officers, directors and 10%+ beneficial owners currently report holdings in RCKTW via SEC Form 4.
Are RCKTW insiders buying or selling?
Across the 50 most recent Form 4 filings for RCKTW, 2 were open-market purchases (code P) and 24 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is RCKTW insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent RCKTW filing is dated 2026-05-28.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the RCKTW quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.